Devasahayam Mercy
INSERM U580, Necker Institute, 161 rue de Sevres, Paris 75015, France.
Indian J Exp Biol. 2007 Aug;45(8):689-95.
Hepatitis B virus core antigen (HBcAg) plays a critical role in terminating acute Hepatitis B virus infection and may be used as a potential vaccine candidate. The cell surface major histocompatibility complex (MHC) class 1 molecules are thought to be involved in the presentation of HBcAg. Surface MHC class 1 HLA A2 heavy chain (HC) and trimeric molecules were characterized on transfected Hela cells used as antigen presenting cells (APC) for the presentation of HBcAg. The results show that antibodies against HC HLA A2 and trimeric HLA-A2 molecules resulted in increased activation of HBcAg 18-27 minimal peptide specific cytotoxic T lymphocytes (CTLs), while the addition of exogenous beta2-microglobulin decreased the activation of HBcAg specific CTLs. Further, specific CD8+ T cells were activated only when Hela cells as APCs were primed with HBcAg (peptide, soluble or embedded on virosomes) at pH 6.5.
乙肝病毒核心抗原(HBcAg)在终止急性乙肝病毒感染中起关键作用,可能用作潜在的疫苗候选物。细胞表面主要组织相容性复合体(MHC)I类分子被认为参与HBcAg的呈递。表面MHC I类HLA A2重链(HC)和三聚体分子在用作呈递HBcAg的抗原呈递细胞(APC)的转染HeLa细胞上得到了表征。结果表明,针对HC HLA A2和三聚体HLA - A2分子的抗体导致HBcAg 18 - 27最小肽特异性细胞毒性T淋巴细胞(CTL)的激活增加,而添加外源性β2-微球蛋白则降低了HBcAg特异性CTL的激活。此外,仅当作为APC的HeLa细胞在pH 6.5下用HBcAg(肽、可溶性或包埋在病毒体上)致敏时,特异性CD8 + T细胞才被激活。